Lubiprostone D7
| Product Name | Lubiprostone D7 |
|---|---|
| Alternate Names | Lubiprostone Stable Isotopes, Stable Isotopes of Lubiprostone |
| CAT No. | CS-O-06737 |
| CAS No. | 1217675-13-2 |
| Category | Stable Isotopes |
| Stock | IN-Stock |
| Mol. Wt. | 397.51 g/mol |
| Mol. For. | C₂₀H₂₅D₇F₂O₅ |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Lubiprostone |
| Purity | 95% |
| Therapeutic | Prostaglandins |
| Smileys | O=C(C(F)(F)CC([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])CC[C@@H]([C@@H](C1)O)[C@H](C1=O)CCCCCCC(O)=O |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Lubiprostone D7 is a deuterated analog of Lubiprostone, which is a medication used to treat chronic idiopathic constipation and irritable bowel syndrome with constipation. Lubiprostone D7 is an orally administered medication that works by activating chloride channels in the gut, which increases the secretion of fluid in the intestines, thereby promoting bowel movement.
Chemically, Lubiprostone D7 is a derivative of prostaglandin E1 and has a molecular formula of C20H25D7Cl2O5. It has a molecular weight of 433.46 g/mol and is a white to off-white powder that is soluble in water and ethanol.
The recommended dosage of Lubiprostone D7 varies depending on the condition being treated, but typically ranges from 8 to 24 micrograms per day. Lubiprostone D7 is generally well-tolerated, with side effects such as nausea, diarrhea, and abdominal pain being the most commonly reported.
Lubiprostone D7 should be used with caution in patients with a history of bowel obstruction, as it may worsen the condition. It should also not be used during pregnancy or breastfeeding, as its effects on the developing fetus or infant are not known.
In conclusion, Lubiprostone D7 is an effective medication for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation. Its chemical properties and mechanism of action make it a valuable tool in the management of these conditions, but it should be used with caution in certain patient populations.
Get an Instant Quote
Related Compounds
Lubiprostone D9 | O-Tetrahydropyranyl Lubiprostone-d7 |